May 2017

Bedtime Sublingual Transmucosal Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD: Retrospective Analyses of the Mediators and Moderators of Treatment Response

May 2017

Phase 2 Multisite Double-Blind Placebo-Controlled Trial of TNX-102 SL in Military-Related Posttraumatic Stress Disorder (PTSD): Mediators and Moderators of Treatment Response

December 2016

The AtEase Study: A Phase 2 Multicenter Randomized Clinical Trial of the Safety and Efficacy of TNX – 102 SL in the Treatment of Military-Related PTSD

November 2016

Low-Dose Sublingual Cyclobenzaprine (TNX-102 SL) in Military-Related PTSD: Results of a Phase 2 Randomized, Placebo-Controlled Multicenter Trial

November 2016

The Efficacy and Safety of TNX-102 SL, a Sublingual Formulation of Cyclobenzaprine, for the Treatment of Military-Related PTSD

October 2016

A Retrospective Analysis of the Efficacy of TNX-102 SL in Military-Related PTSD: Determining the Appropriate Severity Threshold for Trial Entry Using the Clinician-Administered PTSD Scale for DSM-5

October 2016

Tonix PTSD Awareness Day – October 26, 2016: Dr. Gregory Sullivan – Results of the Phase 2 “AtEase Study” in Military-Related PTSD

October 2016

Tonix PTSD Awareness Day – October 26, 2016: Dr. Jonathan Davidson – A Review of Pharmacotherapy for PTSD

October 2016

Tonix PTSD Awareness Day – October 26, 2016: Dr. Thomas A. Mellman – Focus on Sleep and PTSD Treatment Populations

August 2016

The AtEase Study: Efficacy and Safety of a Low Dose, Bedtime, Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD